ENNO-01
Ennovate Pharma is an early-stage biotech company specializing in developing novel personalized therapies for autoimmune and inflammatory diseases
Our Mission
Ennovate Pharma is developing breakthrough therapeutics addressing refractory and non-responder patients of current cytokine-based standard of care treatments by harnessing the power of innate immunity in inflammatory diseases.
Co-founded by Enable Medicine and General Inception, Ennovate Pharma combines standard of care data with cutting-edge single cell spatial biology data to develop therapeutic antibodies quickly and efficiently. We’re integrating high parameter data to discover novel insights using our proprietary AI/ML algorithms. Our focus is to analyze multiple indications to identify therapeutically tractable cell types and targets.
By anchoring on the IL1R pillar, we engineer next-generation bispecific biologics to address the needs of refractory and non-responder patients in inflammatory diseases.
Team
Candidate Pipeline
Developing precision therapeutics for inflammatory diseases presents the significant challenge of accurately stratifying patients. At Ennovate Pharma, we integrate and apply AI/ML to the combination of standard of care data and advanced data analysis. This comprehensive approach allows us to identify novel biomarkers that categorize patients more precisely. Our use of multiplexing analysis enables us to pinpoint therapeutically relevant cell types and targets, driving the discovery of groundbreaking treatments for patients who do not respond to current therapies.
ENNO-01
News
Press release text with links
15 rue de Huningue, F-68300 Saint-Louis, France
Website development by Visual Science